Introduction
============

Diabetic kidney disease (DKD), as one of the most frequent complications of diabetes, is a major leading cause of end-stage renal disease, accounting for \~50% of cases in the developed world.[@b1-tcrm-12-1721] Medical nutrition therapy can improve diabetic outcomes; therefore, it is highly recommended for the management of type 2 diabetes mellitus (T2DM) and its complications.[@b2-tcrm-12-1721],[@b3-tcrm-12-1721] Nutritional therapy with healthful eating is supported by clinical evidence relevant to DKD. Recent approaches to managing DKD apply an enhanced intake of whole grain (complex, unrefined) that is especially important for DKD prevention at an early stage.[@b4-tcrm-12-1721]

Tartary buckwheat (*Fagopyrum tataricum* Gaertn.; TB) is a traditional herbal and functional food in China, which has been reported to be associated with decreased risk of T2DM.[@b5-tcrm-12-1721],[@b6-tcrm-12-1721] It is rich in nutrients and phytochemicals. Phytochemicals from TB, such as flavonoids and D-chiro-inositol enriched, alleviate increase of postprandial glucose[@b7-tcrm-12-1721] and lower fasting glucose.[@b8-tcrm-12-1721] Protein[@b9-tcrm-12-1721],[@b10-tcrm-12-1721] and flavonoids[@b11-tcrm-12-1721],[@b12-tcrm-12-1721] from TB suppress hypercholesterolemia and improve the lipid profile. Management of hyperglycemia and dyslipidemia is critical to prevent DKD for T2DM patients.[@b1-tcrm-12-1721] A recent study demonstrated the significant protective effect of flavonoids from buckwheat on renal function in T2DM rats.[@b13-tcrm-12-1721] However, few studies have focused on the effect of TB on renal function in humans.

Therefore, the hypothesis that a daily intake of TB will improve DKD risk factors was tested. To support this hypothesis, main outcomes were measured in T2DM patients before and after a 4-week intervention with TB, including urinary albumin to creatinine ratio (UACR), urea nitrogen (UN), serum creatinine (SCr), uric acid (UA), and estimated glomerular filtration rate (eGFR).

Materials and methods
=====================

Subjects
--------

A parallel, randomized, open-label controlled, 4-week dietary intervention trial was performed in Pinggu Hospital of Traditional Chinese Medicine, Beijing, China (Trial registration: chiCTR-IIR-15007600 at <http://www.chictr.org.cn/showproj.aspx?proj=12237>). T2DM patients were recruited according to annual physical examination data. Eligibility was determined through the following inclusion criteria: 1) previously diagnosed as diabetic; 2) duration of T2DM is 5--20 years; 3) eGFR ≥90 mL/min/1.73 m^2^; 4) no history of severe kidney disease, cardiovascular disease, stroke, cancer, or psychological disorders; and 5) not pregnant or lactating women. The sample size was calculated based on a previous study of buckwheat effect on renal protection in T2DM rats.[@b13-tcrm-12-1721] The formula was as follows: N =2\[(*t*~α~ + *t*~β~)*S*/*δ*\][@b2-tcrm-12-1721], where *t*~α~ =1.96, *t*~β~ =1.28, and *S* and *δ* were calculated according to the difference in kidney index in the previous study (11.73±1.58 mg/g vs 10.55±1.29 mg/g).[@b13-tcrm-12-1721] A minimum sample size of 38 participants in each group was calculated with a confidence level of 95% and power of 90%. Considering 20% dropout, there was an aim to recruit 96 participants in total. After the exclusions, patients were divided into random groups using a random number table method with SPSS for WINDOWS 19.0 (SPSS Inc., Chicago, IL, USA). Finally, 104 patients (aged 30--80 years) were screened and completed the study ([Figure S1](#SD1-tcrm-12-1721){ref-type="supplementary-material"}). All subjects provided written informed consent.

Study design
------------

The study protocol was approved by the Chinese Ethics Committee of Registering Clinical Trials (chiECRCT-20160001) and was in accordance with the Declaration of Helsinki of 1975 as revised in 1983. Subjects were randomly assigned to a diet control group (DC group) or a TB intervention group (TB group). All subjects were arranged to receive intensive nutritional education at baseline and every week during follow-up, but the DC group was assigned to consume white rice or wheat flour as daily cereals, while the TB group was assigned to replace a part of rice and wheat with TB foods of equivalent energy (100 g/d). TB foods were made of 100% TB from Guiyang Winner Hi-Tech Development Co. Ltd. (Guizhou, China), which were supplied to patients for free. Patients cooked TB foods for meal according to the standard protocols ([Table S1](#SD2-tcrm-12-1721){ref-type="supplementary-material"}). Dietary intake was assessed by 3-day food records, which included one weekend day. After face-to-face instructions by trained nurses from the clinical nutrition department of the hospital, daily food intakes of each participant were self-recorded using a formulary diet diary every day and summarized by trained investigators each week. Information was analyzed using the nutrition clinic consultation management system (Zhending Health Technology Co. Ltd., Shanghai, China). Compliance was monitored by researchers by weighing uneaten cereal packets returned from patients each week. Together with the daily records of food intake from formulary diet diary, including quantity and frequency of test cereals and other food eaten during the study, compliance with the intervention was determined.

Measurements
------------

Body weight, height, body mass index (BMI), blood pressure, glycated hemoglobin (HbA1c), and glycated albumin (GA) were determined by the method of Zhang et al.[@b14-tcrm-12-1721] Plasma glucose, SCr, blood UA, and blood UN were measured by an automatic analyzer (Olympus AU5400, Tokyo, Japan). UACR was calculated by dividing the urinary albumin concentrations measured with a Hitachi 7600 analyzer (Tokyo, Japan) by the urinary creatinine measured with chemiluminescence immunoassay (Siemens Immulite 2000; Siemens Healthcare GmbH, Erlangen, Germany).

Statistical analyses
--------------------

Data were expressed as the mean ± standard deviation (SD) for continuous variables and the number (percentage) for categorical variables. Equality and normality of variance were checked before any further analysis. The nonnormally distributed variables were normalized by the logarithmic transformations. Baseline characteristics of the two groups were compared using Student's *t*-test or Pearson's *χ*^2^ test as appropriate. Differences in variables between the groups at baseline and 4-week intervention were analyzed using the Student's *t*-test, and differences between baseline and final 4-week intervention were compared using the paired Student's *t*-test. Change from baseline in renal profiles was adjusted for sex, age, BMI at baseline, and baseline values of relevant outcome variables, and the differences were analyzed by an analysis of covariance (ANCOVA, generalized linear model) test. All data were analyzed on an intention-to-treat basis without imputation with SPSS for WINDOWS 19.0, and a two-sided *P*\<0.05 was considered significant.

Results
=======

There was no significant difference in baseline characteristics between the DC and TB groups ([Table 1](#t1-tcrm-12-1721){ref-type="table"}). The TB intake resulted in a higher protein intake after the 4-week intervention (protein, % of energy, 13.73±2.83 vs 15.74±2.84), but the DC group did not (protein, % of energy, 14.22±2.26 vs 13.92±2.13). The diet energy and other nutrients were not changed.

The renal profile showed that a significant difference in the change of UACR from baseline between the DC and TB groups was observed (*P*=0.032). The UACR of the DC group was not affected (*P*=0.485) but that of the TB group was decreased significantly (*P*=0.016). In addition, after the 4-week intervention, the TB group showed lower UN level than the DC group (*P*=0.025), and change from baseline of UN between the two groups was also significant (*P*=0.028). TB treatment resulted in a decrease in UN level (*P*=0.049), but the DC group did not (*P*=0.241) ([Table 2](#t2-tcrm-12-1721){ref-type="table"}). The renal profile in T2DM patients with different DKD stages showed that, compared with the DC group, the TB group inhibited the increase in UACR and decreased UN when UACR \<10 mg/g (*P*\<0.05); UACR of the TB group was also decreased when UACR ≥30 mg/g (*P*\<0.05) ([Table 3](#t3-tcrm-12-1721){ref-type="table"}).

Discussion
==========

DKD is defined according to the classification: macroalbuminuria or microalbuminuria plus diabetic retinopathy.[@b15-tcrm-12-1721] Renal dysfunction at stage I (microalbuminuria) of DKD is probably reversible, so that the management of nutrition therapy or dietary interventions is much more important. The presence of early DKD (stage I) in this study was based on Kidney Diseases Outcome Quality Initiative (KDOQI) criteria[@b16-tcrm-12-1721] (eGFR ≥90 mL/min/1.73 m^2^ and UACR ≥30 mg/g). Normoalbuminuric patients are further classified as having normal (UACR \<10 mg/g) or low albuminuria (UACR 10--29 mg/g), according to the recent definition of the National Kidney Foundation (NKF).[@b17-tcrm-12-1721] Increased UACR represents higher urinary albumin excretion as a risk factor for future kidney disease.[@b1-tcrm-12-1721] In this study, TB intervention resulted in the decrease of UACR, but the DC group did not. Subsequent analysis based on different DKD stages showed that the reduction in UACR of TB treatment was especially effective for the T2DM patients with microalbuminuria (30≤ UACR \<300 mg/g). This finding indicated that TB may improve the renal dysfunction at the stage I of DKD by decreasing urinary albumin excretion.

The improvement of urinary albumin excretion is associated with the protein metabolism. Both quantity and quality of protein and amino acids have been identified to be important for the maintenance of adequate nutritional status in DKD.[@b1-tcrm-12-1721] The TB intake resulted in a higher protein intake after the 4-week intervention and a decrease in UN level. This result was consistent with the significantly decreased UN level in the TB group when UACR \<10 mg/g. Compared with the DC group, TB decreased UN and maintained UACR for the T2DM patients with normal renal function. The decreased UN level and increased protein intake induced by TB intake supported that nitrogen was synthetized to amino acid in the body, and thus, nitrogen metabolism was improved. It indicated that TB might alleviate the renal dysfunction in T2DM patients with normoalbuminuria.

In normo- and microalbuminuric patients with T2DM, extra careful attention should be paid to patients with eGFR ≥120 mL/min/1.73 m^2^ to detect cases with rapidly decreased GFR under the normal range.[@b18-tcrm-12-1721] In this study, eGFR was calculated by the Modification of Diet in Renal Disease (MDRD) equation based on the Chinese patients.[@b19-tcrm-12-1721] As a result, mean values of eGFR in the DC and TB groups were \~130 mL/min/1.73 m^2^, together with that the eGFR of 25% patients were 100--120 mL/min/1.73 m^2^ (15 patients per group) and 65% (34 patients per group) were 120--190 mL/min/1.73 m^2^; it was indicated that T2DM patients showed glomerular hyperfiltration. Glomerular hyperfiltration leads to an increase in urinary albumin excretion and thus causes progression of early DKD in T2DM.[@b20-tcrm-12-1721] In this study, eGFR was decreased significantly in both the DC and TB groups, indicating that diet control for T2DM patients effectively ameliorated glomerular hyperfiltration but TB did not show obviously better effect than rice or wheat during the 4-week intervention.

It has been reported that a protective effect of flavonoids from buckwheat on renal dysfunction induced by T2DM may be due to an inhibition of protein tyrosine phosphatase 1B expression in kidney.[@b13-tcrm-12-1721] Another study showed that buckwheat flavonoids showed improvement in renal function by decreasing SCr in rats.[@b21-tcrm-12-1721] In this study, SCr or UA was not affected by TB intervention. Blood pressure was also not changed significantly in T2DM patients, neither systolic blood pressure (SBP) nor diastolic blood pressure (DBP), although a diet supplemented with TB showed beneficial effects on hypertension by a prevention of renal damage in rats.[@b22-tcrm-12-1721] The prevalence of hypertension was also analyzed after the 4-week intervention, and there was no significant difference between the two groups (57.69% vs 42.31%, *P*=0.117). No significant difference in fasting glucose, HbA1c, and GA between the two groups was observed after the 4-week intervention. These findings indicated that a long-term intervention with larger sample size is still needed in the future to illustrate the mechanism of TB effect on renal function and its correlation with blood glucose or blood pressure in T2DM patients.

There were several limitations of this study. First, the duration of 4-week intervention might be not long enough to detect a difference in blood glucose and blood pressure. Second, the patients at early stage I of DKD were screened to evaluate the TB effect on renal dysfunction, which might be insufficient to detect the considerable changes in GFR or albuminuria of T2DM patients.

Conclusion
==========

The hypothesis that substituting TB for white rice or wheat flour showed an effect on lowering UACR and UN in T2DM patients was accepted. Dietary TB intake probably shows a potential way to prevent renal dysfunction for the T2DM patients with normoalbuminuria and ameliorate the renal function at the early stage of DKD (stage I).

Supplementary materials
=======================

###### 

Flow diagram of the TB intervention trial.

**Abbreviations:** TB, tartary buckwheat; T2DM, type 2 diabetes mellitus; eGFR, estimated glomerular filtration rate.

###### 

Nutritional composition of the TB foods

  Type     Energy, kcal/100 g   Protein, g/100 g   Fat, g/100 g   Carbohydrate, g/100 g   Dietary fiber, g/100 g   Flavonoid, g/100 g
  -------- -------------------- ------------------ -------------- ----------------------- ------------------------ --------------------
  Noodle   370.0                13.16              2.23           68.24                   6.35                     0.11
  Kernel   389.5                14.31              1.16           71.91                   5.95                     0.24
  Powder   374.5                13.72              2.05           66.15                   7.96                     0.33

**Notes:** Patients cooked TB foods for meals according to the standard protocols as follows: TB kernel was steamed with water (kernel:water ratio was 1:1.2 in weight) in rice cooker for 5 min; TB noodle was soaked in boiling water for 15 min; TB powder was brewed by boiling water (powder:water ratio was 1:1.3 in weight). Compliance with the TB intake was enhanced by providing three varieties of TB foods for free to the patients during test period.

**Abbreviation:** TB, tartary buckwheat.

This work was funded by the Agricultural Science and Technology Innovation Program, Chinese Academy of Agricultural Sciences, and China Agriculture Research System (CARS-080D-3).
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###### 

Characteristics of the patients at baseline

  Characteristics                                                          DC group (n=52)   TB group (n=52)   *P*-value
  ------------------------------------------------------------------------ ----------------- ----------------- -----------
  Male, n (%)                                                              23 (44.23)        18 (34.62)        0.316
  Age, years                                                               58.12±9.78        59.46±8.95        0.466
  Duration of diabetes, years                                              9.65 (5--20)      10.09 (5--20)     0.213
  Family history of diabetes, n (%)                                        32 (61.54)        26 (50.0)         0.236
  Hypoglycemic agents, n (%)                                               45 (86.54)        44 (84.62)        0.780
  Antihypertensive agents, n (%)                                           22 (42.31)        18 (34.62)        0.420
  Lipid-lowering agents, n (%)                                             6 (11.54)         10 (19.23)        0.277
  MetS (NCEP ATP III), n (%)[†](#tfn2-tcrm-12-1721){ref-type="table-fn"}   29 (55.77)        33 (63.46)        0.424
  Overweight, n (%)                                                        44 (84.62)        40 (76.92)        0.320
  Hypertension, n (%)                                                      29 (55.77)        22 (42.31)        0.170
  Physical characteristics                                                                                     
   Weight, kg                                                              70.37±10.80       68.72±11.86       0.460
   Height, cm                                                              161.79±8.52       159.58±7.83       0.171
   BMI, kg/m^2^                                                            26.83±3.09        26.84±3.17        0.984
   Fasting glucose, mmol/L                                                 9.63±2.73         9.49±2.99         0.806
   HbA1c, %                                                                7.43±1.15         7.61±1.35         0.456
   GA, %                                                                   20.43±5.57        20.08±4.70        0.727
  Diet intake                                                                                                  
   Energy, kcal/d                                                          1,586.49±458.59   1,572.69±411.17   0.877
   Protein, % of energy/d                                                  13.22±2.26        13.03±2.83        0.951
   Fat, % of energy/d                                                      27.73±7.49        27.17±7.03        0.709
   Carbohydrate, % of energy/d                                             58.13±7.59        59.44±7.81        0.412
   Dietary fiber, g/d                                                      9.23±3.93         9.44±3.94         0.794
   TB intake, g/d                                                          0                 113.63±28.52      \<0.001

**Notes:** Data are mean ± SD or number (%). Proportions were compared by Pearson's *χ*^2^ test, and mean values by Student's *t*-test.

MetS was defined using the NCEP ATP III criteria.

**Abbreviations:** DC, diet control; TB, tartary buckwheat; MetS, metabolic syndrome; NCEP ATP III, National Cholesterol Education Program Adult Treatment Panel III; BMI, body mass index; HbA1c, glycated hemoglobin; GA, glycated albumin; SD, standard deviation.

###### 

Change of renal profile during test period

  Variables                DC group (n=52)            TB group (n=52)                                          *P*-value
  ------------------------ -------------------------- -------------------------------------------------------- -----------
  SBP, mmHg                                                                                                    
   Baseline                136.38±15.11               134.44±14.22                                             0.501
   4 weeks                 139.44±13.43               135.15±13.55                                             0.439
   Change from baseline    3.65 (0.14 to 7.16)        0.12 (−3.39 to 3.63)                                     0.164
  DBP, mmHg                                                                                                    
   Baseline                78.25±9.77                 76.71±10.41                                              0.108
   4 weeks                 76.98±11.90                76.67±10.55                                              0.889
   Change from baseline    −1.17 (−3.73 to 1.39)      −0.14 (−2.70 to 2.43)                                    0.576
  Ln UACR, mg/g Cr                                                                                             
   Baseline                2.37±0.93                  2.43±1.02                                                0.411
   4 weeks                 2.54±1.18                  2.35±1.12[\*](#tfn5-tcrm-12-1721){ref-type="table-fn"}   0.721
   Change from baseline    0.04 (−0.17 to 0.25)       −0.28 (−0.49 to −0.07)                                   0.032
  Blood UN, mmol/L                                                                                             
   Baseline                5.28±1.23                  5.12±1.35                                                0.525
   4 weeks                 5.45±1.27                  4.91±1.16[\*](#tfn5-tcrm-12-1721){ref-type="table-fn"}   0.025
   Change from baseline    0.18 (−0.07 to 0.43)       −0.22 (−0.46 to 0.03)                                    0.028
  SCr, μmol/L                                                                                                  
   Baseline                62.90±15.94                61.46±11.05                                              0.593
   4 weeks                 64.25±15.20                63.90±12.80                                              0.900
   Change from baseline    1.41 (0.08 to 2.74)        2.38 (1.05 to 3.71)                                      0.309
  Blood UA, μmol/L                                                                                             
   Baseline                304.60±82.07               301.88±74.80                                             0.861
   4 weeks                 286.75±72.97               270.69±70.17                                             0.255
   Change from baseline    0.02 (0.00 to 0.03)        0.03 (0.01 to 0.04)                                      0.325
  eGFR, mL/min/1.73 m^2^                                                                                       
   Baseline                133.81±26.26               129.76±22.55                                             0.400
   4 weeks                 121.77±27.21               118.39±23.83                                             0.502
   Change from baseline    −10.63 (−13.86 to −7.40)   −12.78 (−16.01 to −9.55)                                 0.356

**Notes:** Baseline and 4-week data are mean ± SD. Differences of variables between groups are analyzed by Student's *t*-test. Changes from baseline are expressed as mean (95% CI) adjusted for sex, age, BMI at baseline, and baseline values of the relevant outcome variables. Differences between groups are analyzed by the ANCOVA (generalized linear model) test.

Difference is considered to be significant at *P*\<0.05; within-group differences (baseline vs 4 weeks) are compared using the paired Student's *t*-test if the between-group differences are significant.

**Abbreviations:** DC, diet control; TB, tartary buckwheat; SBP, systolic blood pressure; DBP, diastolic blood pressure; Ln, logarithmic transformed; UACR, urinary albumin to creatinine ratio; UN, urea nitrogen; SCr, serum creatinine; UA, uric acid; eGFR, estimated glomerular filtration rate; SD, standard deviation; CI, confidence interval; BMI, body mass index; ANCOVA, analysis of covariance.

###### 

Effect of TB on renal dysfunction in T2DM patients with different DKD stages

  Variables                Normal (UACR \<10)         Low (10≤ UACR \<30)                                                  High (UACR ≥30)                                                                 
  ------------------------ -------------------------- -------------------------------------------------------------------- -------------------------- -------------------------- ------------------------- ----------------------------------------------------------------------
  UACR, mg/g Cr            3.69 (0.87 to 6.51)        0.68[\*](#tfn8-tcrm-12-1721){ref-type="table-fn"} (−1.70 to 3.05)    5.08 (−6.92 to 11.77)      3.83 (−15.52 to 23.19)     11.30 (−26.97 to 49.57)   −30.08[\*](#tfn8-tcrm-12-1721){ref-type="table-fn"} (−66.75 to 6.59)
  Blood UN, mmol/L         0.27 (−0.15 to 0.70)       −0.38[\*](#tfn8-tcrm-12-1721){ref-type="table-fn"} (−0.76 to 0.00)   0.26 (−0.35 to 0.88)       0.07 (−0.47 to 0.62)       −0.23 (−0.89 to 0.42)     −0.09 (−1.07 to 0.89)
  SCr, μmol/L              1.90 (−0.13 to 3.66)       2.50 (0.90 to 4.10)                                                  1.46 (−1.29 to 4.22)       0.50 (−3.09 to 4.09)       −0.40 (−4.61 to 3.81)     4.25 (0.81 to 7.69)
  Blood UA, μmol/L         −20.10 (−39.03 to −1.17)   −36.00 (−55.39 to 16.61)                                             −24.08 (−52.25 to 4.09)    −34.75 (−75.98 to 6.48)    −3.20 (−36.89 to 30.49)   −16.42 (−41.16 to 8.32)
  eGFR, mL/min/1.73 m^2^   −11.76 (−18.07 to −5.44)   −14.60 (−20.14 to −9.06)                                             −15.12 (−21.90 to −8.34)   −12.24 (−15.34 to −9.85)   −8.89 (−16.67 to −1.10)   −12.95 (−23.58 to −2.32)

**Notes:** All patients are divided into subgroups according to the UACR values: normal, normoalbuminuria; low, low microalbuminuria; high, microalbuminuria. All data are mean (95% CI) of changes from baseline adjusted for sex, age, BMI at baseline, and baseline values of the relevant outcome variables.

Differences between groups (DC vs TB) are analyzed by the ANCOVA (generalized linear model) test. Daily intake of TB (mean ± SD) is normal, 113.23±31.20; low, 112.07±28.32; high, 106.95±37.31, respectively.

**Abbreviations:** TB, tartary buckwheat; T2DM, type 2 diabetes mellitus; DKD, diabetic kidney disease; UACR, urinary albumin to creatinine ratio; DC, diet control; UN, urea nitrogen; SCr, serum creatinine; UA, uric acid; eGFR, estimated glomerular filtration rate; CI, confidence interval; BMI, body mass index; ANCOVA, analysis of covariance; SD, standard deviation.
